UnitedHealth's Q2 Will Move The Needle (Earnings Preview)

  • UNH is deeply oversold, with consensus expectations set extremely low ahead of Q2, creating a setup for a relief rally on even modestly negative news. Guidance withdrawal has fueled uncertainty, but re-establishing guidance—even at lower levels—should restore confidence and attract buyers, supporting a recovery. Industry headwinds are likely transitory, with margin normalization expected by 2026; UNH's long-term EPS growth outlook remains robust.